Want to see JP:4889 full AI Analyst Report?
Renascience Inc. (4889) Stock Price & Analysis
4889 Stock Chart & Stats
- Day’s Range
- JPY 965.00 - JPY 1,026.00
- 52-Week Range
- JPY 931.00 - JPY 2,228.00
- Previous Close
- JPY 999.00
- Volume
- 77.30K
- Average Volume (3M)
- 161.02K
- Market Cap
- JPY 13.38B
- Enterprise Value
- JPY 18.26B
- Total Cash (Recent Filing)
- JPY 3.20B
- Total Debt (Recent Filing)
- JPY 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.82
- Next Earnings
- Nov 11, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt Reduction
Zero debt materially improves financial flexibility and reduces interest and refinancing pressure. This gives Renascience greater capacity to withstand operating volatility, preserve assets, and pursue its business plans without the balance-sheet strain associated with higher leverage.
High Gross Margins
Consistently high gross margins indicate that the company retains substantial value after direct costs. If revenue stabilizes and operating expenses are better controlled, this underlying margin structure could provide a foundation for improved profitability and stronger operating leverage over time.
Growing Equity Base
Growth in equity supports a stronger capital base and provides additional capacity to maintain or expand assets. Combined with zero debt, this reduces balance-sheet fragility and gives the company more flexibility to address operational challenges over the next several quarters.
Bears Say
Revenue Contraction
A sharp recent revenue decline, together with historically volatile sales, signals difficulty sustaining demand or commercial scale. Persistent top-line weakness can reduce operating leverage, make fixed costs harder to absorb, and delay any credible path toward consistent profitability.
Persistent Cash Burn
Repeatedly negative operating and free cash flow show that the business is not converting activity into internally generated funding. Ongoing cash burn can constrain investment, weaken financial resilience, and increase the company’s dependence on future funding to sustain operations.
Structural Unprofitability
Recurring operating and net losses indicate that the current business model has not yet demonstrated durable earnings power. The reversal from a one-year profit in 2025 to heavy losses in 2026 further highlights unstable earnings quality and limited confidence in sustained returns.
4889 FAQ
What was Renascience Inc.’s price range in the past 12 months?
What is Renascience Inc.’s market cap?
When is Renascience Inc.’s upcoming earnings report date?
How were Renascience Inc.’s earnings last quarter?
Is Renascience Inc. overvalued?
Does Renascience Inc. pay dividends?
What is Renascience Inc.’s EPS estimate?
How many shares outstanding does Renascience Inc. have?
What happened to Renascience Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Renascience Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Renascience Inc.
Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Toshio Miyata
- Employees
- 3
- Website
- www.renascience.co.jp
- Address
- 2-1 Seiryo-cho, Sendai, 980-8575, JP
Renascience Inc. (4889) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |
